Potential Role of Selenium to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats
Potential Role of Selenium to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats

Rusul Nadheer Albakaa; Fadhil A. Rizij; Rafid M. Ali Hassan

Volume 6, Issue 7 , July 2023, , Pages 1498-1505

https://doi.org/10.26655/JMCHEMSCI.2023.7.3

Abstract
  Abstract: Selenium (SE) is well known for its immune boosting, antioxidant, and anti-tumor properties. Doxorubicin (DOXO), a commonly used chemotherapy drug, causes cardiac-damage by ...  Read More
Anti-Atherosclerotic Effects of Pioglitazon by Interference with Inflammatory and Stress Pathway in Male Rabbits
Anti-Atherosclerotic Effects of Pioglitazon by Interference with Inflammatory and Stress Pathway in Male Rabbits

Hajar Nazar Hashem; Fadhil A. Rizij

Volume 6, Issue 4 , April 2023, , Pages 746-754

https://doi.org/10.26655/JMCHEMSCI.2023.4.5

Abstract
  Atherosclerosis is the leading cause of death worldwide. It is now widely accepted that it is a chronic inflammatory process. Minor inflammation, increased oxidative stress, and lipid ...  Read More
Evaluation of Anti-atherosclerotic Effects of Melatonin Interference with Inflammatory and Oxidative Stress Pathway in Male Rabbits
Evaluation of Anti-atherosclerotic Effects of Melatonin Interference with Inflammatory and Oxidative Stress Pathway in Male Rabbits

Hajar Nazar Hashem; Fadhil A. Rizij

Volume 6, Issue 3 , March 2023, , Pages 559-568

https://doi.org/10.26655/JMCHEMSCI.2023.3.13

Abstract
  Atherosclerosis is the primary cause of death worldwide. It is now commonly acknowledged that it is a persistent inflammatory process. Minor inflammation, increased oxidative stress, ...  Read More
Potential Role of Empagliflozin to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats
Potential Role of Empagliflozin to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats

Rusul Nadheer Albakaa; Fadhil A. Rizij; Rafid M.Ali Hassan

Volume 6, Issue 3 , March 2023, , Pages 613-621

https://doi.org/10.26655/JMCHEMSCI.2023.3.18

Abstract
  Empagliflozin (EMPA), a selective inhibitor of sodium-glucose cotranspoter2 (SGLT2), mainly regulates blood glucose levels. Many different mechanisms illustrated the significant impact ...  Read More